Increasing feasibility and utility of 18F-FDOPA PET for the management of glioma

Abstract

Introduction: Despite radical treatment therapies, glioma continues to carry with it a uniformly poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) generally succumb within two years, even those with WHO Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2-5 and 2 years, respectively. PET imaging with F-18-FDOPA allows in vivo assessment of the metabolism of glioma relative to surrounding tissues. The high sensitivity of F-18-DOPA imaging grants utility for a number of clinical applications

Similar works

This paper was published in UQ eSpace (University of Queensland).

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.